Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$138.78

-0.89 (-0.64%)

, SNY

Sanofi

$47.44

-0.76 (-1.58%)

11:06
06/12/17
06/12
11:06
06/12/17
11:06

Tesaro rallies after web report claims Sanofi interested in buyout

Sanofi (SNY) and at least one other suitor have expressed interest in acquiring Tesaro (TSRO), website Street Insider reports, citing "a person claiming to have knowledge of the matter." The second company is likely Gilead Sciences (GILD), and a deal could be worth $10B, the website speculated. Shares of Tesaro, a frequent subject of takeout conjecture, have rallied off the day's lows and are now up $1.22 to $140.00. The company's market capitalization is around $7.40B.

TSRO

Tesaro

$138.78

-0.89 (-0.64%)

SNY

Sanofi

$47.44

-0.76 (-1.58%)

GILD

Gilead

$64.70

0.58 (0.90%)

  • 13

    Jun

  • 13

    Jun

  • 30

    Jun

TSRO Tesaro
$138.78

-0.89 (-0.64%)

06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/09/17
06/09/17
NO CHANGE

Tesaro tells Janney 'no clinical hold, no suspension' in prostate cancer study
After Tesaro (TSRO) shares saw weakness earlier associated with a notice indicating that enrollment was halted in its Johnson & Johnson (JNJ) partnered prostate cancer study, the company told Janney Capital analyst Debjit Chattopadhyay that there is "no clinical hold, no suspension, no safety issues, nothing going on. The first cohort enrolled quickly and we need to see data before starting to enroll the next group - standard trial conduct... JNJ's screening pool was large due to interest, and screen failure rate was lower than expected. Hence, JNJ stopped screening or they would be at risk of enrolling the whole trial before they get to the first data from run in." The analyst, who expect Tesaro shares to be range bound until peer data and regulatory events, keeps a Neutral rating on the stock, which has recovered all of its earlier losses and is now about flat for the session.
06/09/17
WELS
06/09/17
NO CHANGE
WELS
Tesaro trial suspension 'normal' conduct, says Wells Fargo
Wells Fargo analyst Jim Birchenough says the trial recruitment suspension posted on ClinicalTrials.gov is "normal trial conduct" and does not represent any issues. Tesaro shares, after initially selling off on the news, is unchanged on the day.
SNY Sanofi
$47.44

-0.76 (-1.58%)

06/12/17
LEER
06/12/17
NO CHANGE
Target $493
LEER
Outperform
Regeneron's Dupixent tracking well above consensus, says Leerink
Leerink analyst Geoffrey Porges says prescription trends suggest Regeneron (REGN) and Sanofi's (SNY) Dupixent will "comfortably exceed" current sell-side consensus expectations for this quarter and year. After 10 weeks, the prescription launch trajectory "remains very robust," Porges tells investors in a research note. The analyst views his Q2 sales estimate of $31M, versus the $16M consensus, as "reasonable," and feels full year sales of $200M-300M, versus the consensus of $135-$140M, is likely. He reiterates an Outperform rating on Regeneron shares.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
05/11/17
BREN
05/11/17
DOWNGRADE
BREN
Hold
Sanofi downgraded to Hold from Buy at Berenberg
Berenberg analyst Alister Campbell downgraded Sanofi to Hold citing valuation.
04/11/17
04/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Conviction Buy from Buy at Goldman with analyst Drew Borst saying that the success of "Beauty and the Beast" has increased his confidence in his forecast that FY18 EPS growth will accelerate given the company's promising film slate and its read-through to consumer products. He also sees accelerating profit growth at ESPN given normalizing NBA costs and predicts record results for the Theme Parks segment. Borst keeps a $138 price target on Disney shares. 2. McDonald's (MCD) upgraded to Buy from Neutral at Cleveland Research. 3. Yelp (YELP) upgraded to Overweight from Sector Weight at Pacific Crest with analyst Brad Erickson saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG, GOOGL) and Facebook (FB). 4. Toll Brothers (TOL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall citing "solid demand,strong execution, proven management, a strong luxury housing business, and consistent earnings." 5. Sanofi (SNY) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$64.70

0.58 (0.90%)

05/30/17
JPMS
05/30/17
NO CHANGE
JPMS
Overweight
JPMorgan 'generally encouraged' by Gilead bictegravir data
After Gilead (GILD) announced top-line data from four Phase 3 studies of its HIV combo regimen containing bictegravir, JPMorgan analyst Cory Kasimov said he was "generally encouraged by the news, though not entirely surprised" given the previously communicated Phase 2 results. As he has previously noted, Kasimov thinks the launch of the bictegravir combo in 2018 could be key for Gilead to help maintain market share in the face of continued growth of GlaxoSmithKline's (GSK) dolutegravir combo and a wave of patent expirations. The analyst keeps an Overweight rating on Gilead shares.
05/30/17
LEER
05/30/17
NO CHANGE
Target $74
LEER
Market Perform
Gilead HIV combo data should reassure investors, says Leerink
Leerink analyst Geoffrey Porges said Gilead's (GILD) Phase 3 data for its HIV combination treatment featuring bictegravir should "provide significant reassurance for investors" given that the drug is an essential part of the company's HIV strategy and portfolio and was found to be equal to, though not better than, the "gold standard," namely GlaxoSmithKline's (GSK) dolutegravir combo. Porges, who attributes $12-13 per share in value from bictegravir in his current model for Gilead, notes that his peak global forecast of $10.6B for bictegravir containing combination revenue is nearly double the current consensus peak sales estimate of $5.6B. Porges keeps a Market Preform rating and $74 price target on Gilead shares.
04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
WELS
04/25/17
NO CHANGE
WELS
Gilead Q1 results poised to beat expectations, says Wells Fargo
After analyzing prescription data for January and February, Wells Fargo says that prescriptions of Gilead's HIV and HCV drugs were tracking ahead of expectations. The firm says the company's Q1 results appear on track to beat expectations.

TODAY'S FREE FLY STORIES

03:30
08/23/17
08/23
03:30
08/23/17
03:30
General news
FX Action: USD-CAD has lifted to the upper 1.25s »

FX Action: USD-CAD has…

03:25
08/23/17
08/23
03:25
08/23/17
03:25
General news
FX Action: USD-CAD has lifted to the upper 1.25s »

FX Action: USD-CAD has…

02:45
08/23/17
08/23
02:45
08/23/17
02:45
General news
FX Update: The dollar is trading moderately firmer »

FX Update: The dollar is…

LOW

Lowe's

$75.82

1.97 (2.67%)

, EV

Eaton Vance

$47.16

0.58 (1.25%)

20:25
08/22/17
08/22
20:25
08/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$75.82

1.97 (2.67%)

EV

Eaton Vance

$47.16

0.58 (1.25%)

AEO

American Eagle

$11.21

0.59 (5.56%)

EXPR

Express

$5.49

0.14 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 11

    Sep

  • 12

    Sep

  • 13

    Sep

  • 14

    Sep

  • 15

    Sep

  • 21

    Nov

T

AT&T

$37.98

0.4 (1.06%)

, TWX

Time Warner

$101.80

-0.31 (-0.30%)

19:14
08/22/17
08/22
19:14
08/22/17
19:14
Hot Stocks
Mexico regulators approve AT&T-Time Warner deal »

The Instituto Federal de…

T

AT&T

$37.98

0.4 (1.06%)

TWX

Time Warner

$101.80

-0.31 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

REGI

Renewable Energy

$11.20

0.1 (0.90%)

18:50
08/22/17
08/22
18:50
08/22/17
18:50
Hot Stocks
Renewable Energy CEO: Commerce Dept. move 'victory' for job creation »

The U.S Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

INTC

Intel

$34.65

-0.27 (-0.77%)

18:37
08/22/17
08/22
18:37
08/22/17
18:37
Hot Stocks
Former Intel CFO Stacy Smith to retire at the end of January, 2018 »

In an email, Intel CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 29

    Aug

COL

Rockwell Collins

$124.29

0.6 (0.49%)

18:36
08/22/17
08/22
18:36
08/22/17
18:36
Upgrade
Rockwell Collins rating change at Vertical Research »

Rockwell Collins upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$92.95

1.19 (1.30%)

18:24
08/22/17
08/22
18:24
08/22/17
18:24
Hot Stocks
Salesforce CEO says closed large deal with Veterans Administration »

Says federal government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

WWR

Westwater Resources

$1.32

-0.14 (-9.59%)

18:16
08/22/17
08/22
18:16
08/22/17
18:16
Hot Stocks
Westwater Resources acquires water rights for Columbus Basin Project in Nevada »

Westwater Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:03
08/22/17
08/22
18:03
08/22/17
18:03
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:02
08/22/17
08/22
18:02
08/22/17
18:02
Earnings
ZTO Express reports Q2 earnings per ADS 15c, consensus 14c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

URI

United Rentals

$112.44

4.04 (3.73%)

, CMI

Cummins

$153.10

1.04 (0.68%)

17:48
08/22/17
08/22
17:48
08/22/17
17:48
Hot Stocks
United Rentals acquires power equipment assets from Cummins »

United Rentals (URI) has…

URI

United Rentals

$112.44

4.04 (3.73%)

CMI

Cummins

$153.10

1.04 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

, LZB

La-Z-Boy

$31.25

0.1 (0.32%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Maxim Integrated…

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

LZB

La-Z-Boy

$31.25

0.1 (0.32%)

CREE

Cree

$23.03

0.46 (2.04%)

VNET

21Vianet

$4.58

0.03 (0.66%)

CRM

Salesforce

$92.95

1.19 (1.30%)

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

RARE

Ultragenyx

$58.85

1.94 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

  • 16

    Nov

CRM

Salesforce

$92.95

1.19 (1.30%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
Salesforce says sees FY18 margin up 125-150 bps »

Sees "slight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

17:34
08/22/17
08/22
17:34
08/22/17
17:34
Hot Stocks
Maxim Integrated names Sumeet Gagneja principal accounting officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

CTIC

CTI BioPharma

$3.30

0.01 (0.30%)

17:33
08/22/17
08/22
17:33
08/22/17
17:33
Hot Stocks
CTI BioPharma: Chief Business Officer Matthew Plunkett resigns »

Effective August 22,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$47.84

0.51 (1.08%)

17:32
08/22/17
08/22
17:32
08/22/17
17:32
Syndicate
Breaking Syndicate news story on Unum Group »

Unum Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

FTK

Flotek

$5.50

-0.1 (-1.79%)

17:29
08/22/17
08/22
17:29
08/22/17
17:29
Hot Stocks
Flotek announces conclusion of SEC inquiry »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 16

    May

CRM

Salesforce

$92.95

1.19 (1.30%)

17:24
08/22/17
08/22
17:24
08/22/17
17:24
Hot Stocks
Salesforce says 'had best quarter ever' »

Says can reach $20B in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

THO

Thor Industries

$103.90

0.45 (0.43%)

17:17
08/22/17
08/22
17:17
08/22/17
17:17
Hot Stocks
Jayco announces expansion of Middlebury campus, will add 300 jobs »

Jayco, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$924.69

18.03 (1.99%)

, GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

17:14
08/22/17
08/22
17:14
08/22/17
17:14
Hot Stocks
Google introduces Chrome Enterprise »

Google introduced Chrome…

GOOG

Alphabet

$924.69

18.03 (1.99%)

GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

VNET

21Vianet

$4.58

0.03 (0.66%)

17:11
08/22/17
08/22
17:11
08/22/17
17:11
Earnings
21Vianet reports Q2 EPS (12c), one estimate (11c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

17:05
08/22/17
08/22
17:05
08/22/17
17:05
Hot Stocks
root9B Technologies announces incremental funding, status of foreclosure »

root9B Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:03
08/22/17
08/22
17:03
08/22/17
17:03
Hot Stocks
Gramercy Property Trust launches new JV over Class A distribution centers »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.